🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06735105
Recruiting Not applicable

Study on the Value of Three DWI Scanning Sequences in Staging of Gastric Cancer

NCT06735105 · tracked via the Priya Life Science China tracker
Sponsor
Yunnan Cancer Hospital
Phase
Not applicable
Started
2023-12-23
Last updated
2024-12-16

Condition(s) studied

Gastric Cancer

Investigational drug(s) / intervention(s)

Scanning parameter

Scanning parameter: Based on abdominal scanning, TSE-DWI,ZOOMIT DWI and EPI-DWI scans were performed, and the study was divided into two steps according to the nanomotion criteria. The first step was self-controlled, which was divided into experimental group and control group. The experimental group included TSE-DWI,ZOOMit DWI, and the control group included EPI-DWI. Then the image quality was evaluated by subjective and objective evaluation indexes. In the second step, the three DWI stages were performed separately by four diagnosticians, with an interval of 1 month, and statistical analysis was performed at the end.

Study summary

Accurate staging is critical for effective gastric cancer treatment planning. Conventional DWI (C-DWI) has limitations in image quality due to magnetic field inhomogeneity, which hampers precise T staging.

This study aims to compare the image quality and T staging accuracy of C-DWI, TSE-DWI, and ZOOMit-DWI (Z-DWI) sequences in MRI examinations of gastric cancer patients.

A prospective study plan to enroll 72 gastric cancer patients undergoing preoperative MRI with C-DWI, TSE-DWI, and Z-DWI sequences using a 3.0 T scanner. Quantitative metrics (ADC, SNR, CNR) and image quality were evaluated. T staging accuracy was assessed by comparing MRI results with postoperative pathological staging using ROC analysis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. The patient was diagnosed with gastric cancer by pathological biopsy 2. No biopsy was taken within 1 week before MR Examination to rule out the effect of bleeding on the image 3. No contraindications for MRI examination; And exclude serious heart, liver, kidney, cerebrovascular diseases. Exclusion Criteria: 1. The image quality cannot meet the diagnostic criteria; 2. Patients could not tolerate MRI examination, resulting in incomplete MR-related sequence image data.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Yunnan Cancer Hospital Kunming China Recruiting

More Yunnan Cancer Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06735105 on ClinicalTrials.gov ↗ ← All trials in China